COMMITTED TO DEVELOPING TARGETED TREATMENTS FOR
DIFFICULT TO TREAT ADVANCED CANCERS

ALONBIO LTD

AlonBio is an oncology biotechnology company focused on discovering and developing targeted cancer therapies. We identify and target key drivers of cancer cell growth, resistance, and survival.
Our core competencies in cancer biology research and drug development, taken together with our small molecule screening platforms enable a rapid translation of our discoveries into potential treatments for difficult-to-treat aggressive cancers.

Our lead asset BKT300 is a novel, first-in-class, highly selective, PRC1 inhibitor developed as a targeted anti-cancer treatment.

ESTABLISHED LEADERSHIP

We have assembled an experienced management team with deep expertise in oncology research and drug development. and a demonstrated track record of success building biotech companies and developing novel therapeutics.

Professor. Amnon Peled, Ph.D

CEO, CSO

H. Laurence Shaw, M.D

Chairman of the Board

Michal Abraham-Karni Ph.D

Head of Pre-Clinical Development

Leadership

BOARD OF DIRECTORS

H. Laurence Shaw, M.D.

Chairman

Prof. Amnon Peled, Ph.D.

CEO, CSO

Shmuel Cabilly, Ph.D.

Director

Alex Trevor Stanton